Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Alterity Therapeutics ( (ATHE) ).
Alterity Therapeutics Limited announced that its next Annual General Meeting (AGM) is scheduled for November 21, 2025. The closing date for director nominations is set for October 1, 2025. This announcement is a routine part of the company’s governance process, providing stakeholders with important dates for participation in corporate decision-making.
The most recent analyst rating on (ATHE) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the ATHE Stock Forecast page.
Spark’s Take on ATHE Stock
According to Spark, TipRanks’ AI Analyst, ATHE is a Neutral.
The overall stock score for Alterity Therapeutics is primarily impacted by its challenging financial performance, with persistent losses and negative cash flows posing significant risks. However, technical analysis indicates strong upward momentum, which partially offsets the negative financial outlook. The poor valuation due to a negative P/E ratio further depresses the score. Without earnings call insights or new corporate events, the score reflects the current financial and technical conditions.
To see Spark’s full report on ATHE stock, click here.
More about Alterity Therapeutics
Alterity Therapeutics Limited is a development stage enterprise in the biotechnology industry, focusing on the development of therapeutic products. The company is listed on the Australian Securities Exchange (ASX) and NASDAQ, indicating its involvement in the global market.
Average Trading Volume: 83,476
Technical Sentiment Signal: Hold
Current Market Cap: $78.89M
See more insights into ATHE stock on TipRanks’ Stock Analysis page.